Iwaaki Taniguchi - Takeda Pharmaceutical Sr Department
| TKPHF Stock | USD 25.26 0.29 1.14% |
Insider
Iwaaki Taniguchi is Sr Department of Takeda Pharmaceutical Co
| Phone | 81 3 3278 2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0477 %, meaning that it generated $0.0477 on every $100 dollars invested by stockholders. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Naoki BSc | Astellas Pharma | N/A | |
| Dirk Toepfer | Merck KGaA ADR | N/A | |
| Minoru Kikuoka | Astellas Pharma | N/A | |
| Catherine Levitt | Astellas Pharma | N/A | |
| Marielle MD | Daiichi Sankyo | N/A | |
| Matthias Heinzel | Merck KGaA ADR | 56 | |
| Katsuyoshi Sugita | Astellas Pharma | N/A | |
| Collette Taylor | Astellas Pharma | 60 | |
| Gabriel Harnier | Bayer AG | 52 | |
| Barbara Weiland | Merck KGaA ADR | 49 | |
| Hideyuki Haruyama | Daiichi Sankyo | N/A | |
| Rodrigo Santos | Bayer AG | 50 | |
| Toshiya Sasai | Chugai Pharmaceutical Co | N/A | |
| Kentaro Asakura | Daiichi Sankyo | N/A | |
| Junichi Onuma | Daiichi Sankyo | N/A | |
| Belen MD | Merck KGaA ADR | 63 | |
| Michael Preuss | Bayer AG | N/A | |
| Oliver Maier | Bayer AG | N/A | |
| Gerhard Schmitz | Merck KGaA ADR | 60 | |
| BerndPeter Bier | Bayer AG | 56 | |
| Yoshinori Kaneshima | Daiichi Sankyo | N/A | |
Management Performance
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christophe Weber, CEO and President and Representative Director | ||
| Christopher OReilly, Global Fin | ||
| Andrew Plump, Chief Medical and Scientific Officer and Corporate Officer | ||
| Seigo Izumo, Chair Board | ||
| Gabriele Ricci, Chief Officer | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Sr Department | ||
| Constantine Saroukos, CFO Director | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 75.53 B | |||
| Shares Outstanding | 1.56 B | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 41.35 % | |||
| Price To Earning | 27.54 X | |||
| Price To Book | 0.97 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Takeda Pink Sheet
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.